Results 41 to 50 of about 16,465 (200)

Supplementary Fig. S.1 from NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

, 2017
Sequences of IL12 conjoined regions of MG1-IL12 and G-less MRB-IL12 viruses.
Abhirami A. Ananth (2794732), Andrew P. Makrigiannis (14911220), E. Celia Marginean (15115049), Jiqing Zhang (419946), Michael A. Kennedy (230327), Shalini Sahi (14991576), Greg O. Cron (9936684), Blair Macdonald (15115046), Charles Lefebvre (15114515), Almohanad A. Alkayyal (2794729), Christiano Tanese de Souza (2794726), Ahmad Bakur Mahmoud (13946295), David F. Stojdl (14049867), Rebecca C. Auer (2794744), John C. Bell (206340), Lee-Hwa Tai (2794741)   +15 more
core   +1 more source

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Oncotarget, 2014
Targeted delivery of IL-12 might turn this cytokine into a safer, more effective cancer therapeutic. Here we describe a novel immunocytokine, NHS-IL12, consisting of two molecules of IL-12 fused to a tumor necrosis-targeting human IgG1 (NHS76). The addition of the human IgG1 moiety resulted in a longer plasma half-life of NHS-IL12 than recombinant IL ...
Jonathan, Fallon, Robert, Tighe, Giorgio, Kradjian, Wilson, Guzman, Anna, Bernhardt, Berend, Neuteboom, Yan, Lan, Helen, Sabzevari, Jeffrey, Schlom, John W, Greiner   +9 more
openaire   +3 more sources

Construction and characterization of AdCN205-IL12.

, 2012
(A) Schematic description of the structures of AdCN103, AdCN205-GFP and AdCN205-IL12. In AdCN103, the E1A promoter was replaced by hTERT promoter and deletion of the adenoviral genome 923 to 946 nucleotides, which enables viral replication within ...
Junjie Shen (134885), Limei Liu (134888), Ke Xu (134879), Xia Zhang (41398), Xiu-wu Bian (134899), Cheng Qian (132529), Zhi Yang (124104), Youhong Cui (134896), Yanmin Xu (134890), Qianzhen Zhang (134876), Feng Xia (134893), Juanjuan Shan (134882), Ping Bie (134894)   +12 more
core   +1 more source

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

Journal for ImmunoTherapy of Cancer, 2020
Background Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months.
Dipongkor Saha, Samuel D Rabkin, Robert L Martuza   +2 more
doaj   +1 more source

Gemini Cationic Lipid-Type Nanovectors Suitable for the Transfection of Therapeutic Plasmid DNA Encoding for Pro-Inflammatory Cytokine Interleukin-12

Pharmaceutics, 2021
Ample evidence exists on the role of interleukin-12 (IL-12) in the response against many pathogens, as well as on its remarkable antitumor properties. However, the unexpected toxicity and disappointing results in some clinical trials are prompting the ...
Natalia Sánchez-Arribas, María Martínez-Negro, Clara Aicart-Ramos, Conchita Tros de Ilarduya, Emilio Aicart, Andrés Guerrero-Martínez, Elena Junquera   +6 more
doaj   +1 more source

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab

Therapeutic Advances in Gastroenterology, 2022
As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD) increases, the therapeutic armamentarium for its treatment can expand, and novel target therapies join the treatment pipeline. Interleukin (IL)-12 and IL23 are two key cytokines responsible for promoting and perpetuating bowel inflammation in IBD.
Pugliese, Daniela, Privitera, Giuseppe, Fiorani, Marcello, Parisio, Laura, Calvez, Valentin, Papa, Alfredo, Gasbarrini, Antonio, Armuzzi, Alessandro   +7 more
openaire   +3 more sources

miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen−/− Immunization

Frontiers in Immunology, 2019
No vaccine exists against visceral leishmaniasis. Toward developing vaccines against VL, we have reported previously on the immunogenicity of live attenuated LdCen−/− parasites in animal models.
Sreenivas Gannavaram, Parna Bhattacharya, Abid Siddiqui, Nevien Ismail, Subha Madhavan, Hira L. Nakhasi   +5 more
doaj   +1 more source

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

OncoImmunology, 2023
The tumor microenvironment (TME) in ovarian cancer (OC) is characterized by immune suppression, due to an abundance of suppressive immune cells populations.
Paul G. Pavicic, Patricia A. Rayman, Shadi Swaidani, Amit Rupani, Vladimir Makarov, Charles S. Tannenbaum, Robert P. Edwards, Anda M. Vlad, C. Marcela Diaz-Montero, Haider Mahdi   +9 more
doaj   +1 more source

Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity

Scientific Reports
Cytokines play pivotal roles in anticancer immune response. We previously reported that adenovirus armed with an IL18 variant (DR18) that overcomes IL18BP neutralizing effect displayed powerful therapeutic effects in local and distant tumors when ...
Yan Cheng, Renjie Luo, Erguang Li
doaj   +1 more source

Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL‐23/CD93 Pathways in Muscle

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Genetic modifiers of Duchenne muscular dystrophy (DMD) that alter disease severity or response to therapy have been reported using natural history or registry data sets of older corticosteroid‐treated patients. We tested associations of genetic modifiers on motor function outcomes in young (4 to < 7 years) steroid naïve clinical trial ...
Utkarsh J. Dang, Yuan Fang, Daniele Sabbatini, Elena Pegoraro, Luca Bello, Paula R. Clemens, Michela Guglieri, John van den Anker, Jesse Damsker, Laura Hagerty, Yetrib Hathout, Michael Ziemba, Lauren Morgenroth, Surajit Bhattacharya, Kanneboyina Nagaraju, Jyoti K. Jaiswal, Eric P. Hoffman   +16 more
wiley   +1 more source